J&J nabs option to buy ‘in vivo’ CAR-T maker Sail for nearly $2.6B
The deal with the buzzy Flagship Pioneering-backed startup makes J&J the latest large drugmaker to bet that the technology might be able to treat autoimmune conditions.
Read the full article on the original site.
Read Full Article